NASDAQ$NRIX
Nurix Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Reported financial results for the fourth quarter and fiscal year ended November 30, 2024, and provided a corporate update.
Nurix Therapeutics reported Q4 revenue of $13.3 million and a net loss of $58.5 million, or ($0.75) per share. The company's cash, cash equivalents, and marketable securities totaled $609.6 million as of November 30, 2024.
- Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL.
- Received PRIME designation from the European Medicines Agency for NX-5948 in CLL.
- Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom’s Macroglobulinemia.
- Announced the appointment of John Northcott as Chief Commercial Officer.
Headline financials
Revenue & EPS history
Nurix · Revenue · Quarterly
$13.3M
Revenue by segment
Nurix · $18.5M total across 1 segment · Q3 2023
- Collaboration revenue$18.5M+71.1%100.0%
Forward guidance
Nurix plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL and to explore its development in inflammatory diseases.
Tailwinds
- Plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL.
- Exploring development of NX-5948 in inflammatory diseases.
- Initiating clinical testing of NX-5948 in autoimmune cytopenias in 2025.
- Advancing a pipeline of wholly owned and partnered programs in inflammation and immunology.
- Expecting clinical updates in patients with both CLL and non-Hodgkin’s lymphoma in 2025.
Headwinds
- Uncertainties related to the timing and results of preclinical studies and clinical trials.
- Whether Nurix will be able to fund development activities and achieve development goals.
- Uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners.
- The impact of global business, political and macroeconomic conditions on Nurix’s business.
- Whether Nurix will be able to protect intellectual property.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+2.9%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.8%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+35.6%
Q1 2023
Best reaction
-13.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -4.2% | +4.5% | +5.9% | |
| Q4 2025 | -1.7% | -6.0% | -10.6% | |
| Q3 2025 | -10.1% | -4.7% | +13.4% | |
| Q2 2025 | -4.3% | -11.7% | -16.8% | |
| Q1 2025 | +7.8% | +12.0% | +4.8% | |
| Q4 2024 | +0.5% | -3.1% | -21.0% | |
| Q3 2024 | +15.1% | +18.1% | +25.1% | |
| Q2 2024 | +17.7% | +12.7% | +2.9% | |
| Q1 2024 | -1.5% | -11.6% | -22.7% | |
| Q4 2023 | +7.2% | +9.6% | +42.0% | |
| Q3 2023 | -3.9% | -8.3% | -20.5% | |
| Q2 2023 | -2.2% | -2.3% | -7.3% | |
| Q1 2023 | +35.6% | +29.9% | +14.8% | |
| Q4 2022 | +1.0% | -6.2% | -25.8% | |
| Q3 2022 | -13.2% | -12.6% | +2.5% | |
| Q2 2022 | +22.7% | +10.7% | +34.3% | |
| Q1 2022 | +7.2% | -3.7% | -30.8% | |
| Q4 2021 | -4.6% | +2.3% | -14.1% | |
| Q3 2021 | +0.1% | -1.6% | +18.3% | |
| Q2 2021 | -5.1% | +8.6% | +32.2% | |
| Q2 2020 | -5.1% | +8.6% | +32.2% | |
| Q1 2021 | +12.6% | +9.0% | -5.4% | |
| Q4 2020 | +3.0% | -4.2% | -1.3% | |
| Q3 2020 | -4.7% | +3.8% | +14.4% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro